🔎 Trials Near Me

Home › Acute Lymphoblastic Leukemia › Ohio

Acute Lymphoblastic Leukemia clinical trials in Ohio

21 studies for Acute Lymphoblastic Leukemia are looking for participants at sites in Ohio.

Cities in Ohio

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  • Oncology Hematology Care, Cincinnati
  • Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 2
6 Months · All sexes · Updated Sep 28, 2026 · NCT06514794

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Ohio State University, Columbus
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06904482

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland
  • The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1/2
Ages 16 to 75 · All sexes · Updated Sep 10, 2026 · NCT03104491

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • and 44 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies and Childrens Hospital, Cleveland
  • and 3 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

  • Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
1 Day – 17 Years · All sexes · Updated Aug 14, 2026 · NCT06274788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Childrens Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital, Cincinnati
  • University Hospitals Case Medical Center, Cleveland
  • and 3 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

  • Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1/2
Up to age 21 · All sexes · Updated Jun 3, 2026 · NCT04195347

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 2 and older · All sexes · Updated May 29, 2026 · NCT05418088

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

  • Ohio State University Medical Center, Columbus
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Mar 25, 2026 · NCT03533816

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • Cleveland Clinic Foundation, Cleveland
RecruitingPhase 2
Ages 18 to 54 · All sexes · Updated Mar 17, 2026 · NCT06918431

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022

HPC Offered for PRESERVE Expansion

  • The Ohio State University Medical Center, Columbus
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Aug 28, 2025 · NCT07145411

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies, Cleveland
  • Nationwide Children's Hospital, Columbus
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.